TroClose 1200

Exclusive Global Class III Innovative Medical Device · A Game-Changer in Laparoscopic Surgical Access

As the world’s first integrated “puncture-suturing” laparoscopic trocar, TroClose 1200^TM has successfully completed FDA registration and undergone clinical validation in China, filling a significant technological gap in laparoscopic incision closure.

1. Project Background

TroClose 1200 is an exclusive Class III innovative medical device introduced by Lujian Technology from Israel in 2022. Supported by the Israeli Innovation Authority for research and development, Lujian Technology has completed its domestic transformation and technology commercialization

Developed by Israeli surgeons and technical teams, the product received a $10 million investment from global medical giant B. Braun. After several years of R&D, it gained FDA and CE certifications in 2016 and has been marketed in Israel, Turkey, Latin America, and other regions. With over 3,000 clinical applications in the U.S. and Germany, the product received a surgeon satisfaction rating of 9.8/10.

Following its introduction to China, Lujian Technology optimized the product design, process stability, manufacturing adaptability, and registration pathway based on both Chinese and international market and clinical demands. Through collaboration between Chinese and international engineers, TroClose 2.0 was developed and FDA certified, transforming the project from a laboratory innovation into a clinically applicable and commercially viable medical device.

Patented Technology · Global IP Protection

The TroClose series is protected by a comprehensive global patent network, with over 30 core patents. The technology barriers cover key medical markets in the U.S., Europe, and China. With this patent protection, Lujian Technology holds the exclusive global manufacturing rights and exclusive commercialization rights for the product in China.

2. Product Introduction

TroClose 1200 consists of an obturator and a cannula, designed for various gynecological, general surgical, and urological endoscopic surgeries. It is used to create and maintain an access channel and to suture the channel post-operatively. The device features an innovative 180-degree suture placement system, forming a half-loop knot structure. Compared to traditional full-loop knots, this structure significantly reduces tissue tension, ensuring surgical safety while enhancing operational convenience and lowering overall costs. Its unique design, stable operational performance, and single-use sterile standards make it suitable for multiple laparoscopic surgical scenarios, fully meeting clinical infection control requirements.

Product Advantages:

Integrated Design: Combines puncturing and suturing functions, reducing the need for multiple instruments and steps.

Zero Hernia Risk: Clinical validation shows a 0% hernia occurrence rate post-operation, eliminating incision hernia risks.

High-Efficiency Surgery: Half-loop knot technology reduces incision tension by 75%, saving an average of 20 minutes in surgery time.

Clinically Easy to Use: Short learning curve, allowing surgeons to use the device reliably without complex training.

Cost-Efficiency and Safety: Reduces surgical instrument use and complication treatment costs, accelerating patient recovery.

3. Market Outlook

According to research from the China Medical Device Industry Association, with the rapid adoption of minimally invasive endoscopic surgery in China, the market demand for trocars, which are essential for endoscopic procedures, is expected to maintain high growth. From 2020 onwards, China’s trocar market is forecasted to grow at a compound annual growth rate (CAGR) of 17.5%. In 2020, the market size for trocars reached ¥9.636 billion. Conservatively, by 2026, the market size for trocars in China is expected to reach ¥30 billion